MAPT and supranuclear palsy, progressive, 1: We also confirmed that when we tested on individual Phospho-Null Variants 1 through 5, both AD patient-derived tau seeds (Additional file 1: Fig. S3f-h) and PSP patient-derived tau seeds (Additional file 1: Fig. S3m-o) showed equivalent tau seeding efficiency compared to the other variants.